LIGOCYTE PHARMACEUTICALS
LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply treating the resulting symptoms. LigoCyte is advancing its proprietary products into human clinical testing, positioning the company for continued growth and success in the biotechnology industry.
LIGOCYTE PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1998-01-01
Address:
Bozeman, Montana, United States
Country:
United States
Website Url:
http://www.ligocyte.com
Total Employee:
11+
Status:
Active
Contact:
406-585-2733
Total Funding:
43.56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Content Delivery Network Amazon OpenResty Google Adsense AdBlock Acceptable Ads Google Adsense For Domains Bodis DNS
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Current Employees Featured
Investors List
JAFCO
JAFCO investment in Series C - LigoCyte Pharmaceuticals
MedImmune Ventures
MedImmune Ventures investment in Series C - LigoCyte Pharmaceuticals
Athenian Venture Partners
Athenian Venture Partners investment in Series C - LigoCyte Pharmaceuticals
Novartis Venture Fund
Novartis Venture Fund investment in Series C - LigoCyte Pharmaceuticals
Forward Ventures
Forward Ventures investment in Series C - LigoCyte Pharmaceuticals
Eight Roads Ventures
Eight Roads Ventures investment in Venture Round - LigoCyte Pharmaceuticals
Official Site Inspections
http://www.ligocyte.com
- Host name: 199.59.243.227
- IP address: 199.59.243.227
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "LigoCyte Pharmaceuticals"
LigoCyte Pharmaceuticals - Crunchbase Company Profile & Funding
LigoCyte Pharmaceuticals is focused on developing vaccines and monoclonal antibodies for gastrointestinal and respiratory indications. LigoCyte is breaking new ground in the treatment …See details»
Takeda Pharmaceuticals North America, Inc.
Oct 4, 2012 · LigoCyte is a privately-held biopharmaceutical company specializing in innovative vaccine products headquartered in Bozeman, Montana. Its lead product, a vaccine to prevent …See details»
LigoCyte Pharmaceuticals, Inc. (LigoCyte Pharmaceuticals, Inc.) - 药 …
In this review we will discuss the role of scavenger receptors in AM binding of unopsonized particles and the use of flow cytomety in analyzing AM-particle interaction. We will also …See details»
LigoCyte - Products, Competitors, Financials, Employees, …
Ligocyte is a vaccine discovery and development company. It develops vaccines and therapeutic monoclonal antibodies for the respiratory and gastrointestinal markets. It provides biodefense …See details»
Takeda to Acquire LigoCyte Pharmaceuticals, Inc. - PR Newswire
Oct 4, 2012 · LigoCyte is a privately-held biopharmaceutical company specializing in innovative vaccine products headquartered in Bozeman, Montana. Its lead product, a vaccine to prevent …See details»
Ligocyte Pharmaceuticals - PitchBook
Developer of vaccines and therapeutic monoclonal antibodies for respiratory and gastrointestinal markets. The company focuses on developing commercial vaccines, biodefense vaccines, and …See details»
Takeda to Acquire LigoCyte Pharmaceuticals, Inc. - CNBC
Oct 4, 2012 · LigoCyte is a privately-held biopharmaceutical company specializing in innovative vaccine products headquartered in Bozeman, Montana. Its lead product, a vaccine to prevent …See details»
Takeda acquires LigoCyte Pharmaceuticals - 2012-10-05
Oct 5, 2012 · LigoCyte Pharmaceuticals LigoCyte Pharmaceuticals is focused on developing vaccines and monoclonal antibodies for gastrointestinal and respiratory indications. Acquiring …See details»
Takeda buys vaccine maker LigoCyte | Reuters
Oct 4, 2012 · (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T> said it would buy privately held U.S. company LigoCyte Pharmaceuticals Inc for an upfront payment of $60 …See details»
LigoCyte Pharmaceuticals - Contacts, Employees, Board Members, …
LigoCyte Pharmaceuticals is focused on developing vaccines and monoclonal antibodies for gastrointestinal and respiratory indications.See details»
Takeda pays $60m for vaccine company LigoCyte - PMLiVE
Oct 8, 2012 · The deal for LigoCyte adds a first-in-class norovirus vaccine candidate and the Montana-based firm’s virus-like particle platform (VLP) technology to the vaccines division …See details»
Takeda to Acquire LigoCyte Pharmaceuticals
Oct 5, 2012 · Takeda Pharmaceutical Company Limited and LigoCyte Pharmaceuticals, Inc. jointly announced today that Takeda’s wholly-owned subsidiary, Takeda America Holdings, …See details»
Takeda builds up new vaccine unit with $60M LigoCyte buyout
Oct 5, 2012 · The U.S. unit of the Japanese drug giant has agreed to acquire Bozeman, MT-based LigoCyte for $60 million, with potential future payouts that were undisclosed, Takeda …See details»
Takeda to Acquire LigoCyte Pharmaceuticals, Inc.
Oct 4, 2012 · LigoCyte is a private, clinical-stage biopharmaceutical company focused on developing novel vaccines for gastrointestinal and respiratory indications. LigoCyte's expertise …See details»
Data From LigoCyte's Clinical Studies of Norovirus VLP Vaccine ...
Apr 28, 2010 · LigoCyte is a private, clinical-stage biotechnology company focused on developing novel vaccines for gastrointestinal and respiratory indications. LigoCyte's expertise in virus-like …See details»
Positive Results From LigoCyte's Norovirus Vaccine Challenge …
BOZEMAN, Mont., Oct. 25 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing innovative vaccine products, today announced …See details»
Research programme: biodefence vaccines and therapeutics
LigoCyte is collaborating with the US Army's Medical Research Institute of Infectious Diseases (USAMRIID) and Walter Reed Army Institute of Research to developSee details»
LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent ...
Sep 16, 2010 · LigoCyte is a private, clinical-stage biopharmaceutical company focused on developing novel vaccines for gastrointestinal and respiratory indications. LigoCyte's expertise …See details»
LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent ...
Sep 16, 2010 · LigoCyte's bivalent vaccine is designed to provide protection against group I noroviruses with its GI.1 VLP antigen and against group II noroviruses with its GII.4 VLP …See details»
Research programme: anti-CD62 monoclonal antibodies - LigoCyte
LigoCyte Pharmaceuticals is developing monoclonal antibodies targeted to CD62 for the treatment of chronic obstructive pulmonary disease (COPD) and acuteSee details»